Press Releases

NASHUA, NH, and TORONTO, CANADA, March 05, 2025 — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across…

NASHUA, NH, and CHICAGO, IL, February 26, 2025 — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection….

NASHUA, N.H. – February 19, 2025 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company’s advancements in…

iCAD to Participate in the BTIG at Snowbird: 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference NASHUA, NH., January 27, 2025 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader on a mission to create a world where cancer can’t hide by…

Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment NASHUA, N.H., December 11, 2024 — iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel…

ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 NASHUA, N.H., November 26, 2024 — iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking…

NASHUA, N.H. – November 13, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months…

NASHUA, N.H., November 12, 2024 — iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Administration (FDA). This next-generation…

NASHUA, N.H. – Nov 6, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will…

NASHUA, N.H., November 5, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday,…